CS
Candriam SCA Portfolio holdings
AUM
$17.3B
1-Year Return
21.68%
This Quarter Return
+8.31%
1 Year Return
+21.68%
3 Year Return
+102.54%
5 Year Return
+176.54%
10 Year Return
+489.52%
AUM
$5.17B
AUM Growth
+$808M
(+19%)
Cap. Flow
+$413M
Cap. Flow
% of AUM
8%
Top 10 Holdings %
Top 10 Hldgs %
16.85%
Holding
725
New
51
Increased
415
Reduced
155
Closed
32
Top Buys
| 1 |
CELG
Celgene Corp
CELG
|
+$45.5M |
| 2 |
Gilead Sciences
GILD
|
+$39.4M |
| 3 |
GE Aerospace
GE
|
+$36.8M |
| 4 |
Motorola Solutions
MSI
|
+$26M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
+$24.4M |
Top Sells
| 1 |
Johnson & Johnson
JNJ
|
+$55.4M |
| 2 |
Amgen
AMGN
|
+$30M |
| 3 |
MJN
Mead Johnson Nutrition Company
MJN
|
+$23.3M |
| 4 |
Canadian National Railway
CNI
|
+$21.7M |
| 5 |
Becton Dickinson
BDX
|
+$18.5M |
Sector Composition
| 1 | Healthcare | 24.05% |
| 2 | Financials | 13.76% |
| 3 | Technology | 12.92% |
| 4 | Communication Services | 9.3% |
| 5 | Consumer Staples | 7.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
426
CMS Energy
CMS
$21.2B
| $2.05M | 0.04% |
45,751
-441
| -1% | -$19.7K |
|
427
ODP
ODP
$642M
| $2.05M | 0.04% |
43,884
| – | – |
|
428
PPL Corp
PPL
$26.4B
| $2.05M | 0.04% |
54,757
+11,435
| +26% | +$427K |
|
429
Moody's
MCO
$91B
| $2.05M | 0.04% |
18,250
+5,066
| +38% | +$568K |
|
430
HUTCHMED
HCM
$2.77B
| $2.04M | 0.04% |
+102,000
| New | +$2.04M |
|
431
McKesson
MCK
$86.7B
| $2.03M | 0.04% |
13,715
+3,398
| +33% | +$504K |
|
|
AKAO
432
DELISTED
Achaogen, Inc.
AKAO
| $2.03M | 0.04% |
80,555
-9,445
| -10% | -$238K |
|
|
OMED
433
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $1.97M | 0.04% |
214,000
+7,000
| +3% | +$64.5K |
|
434
Prologis
PLD
$105B
| $1.94M | 0.04% |
37,424
+6,223
| +20% | +$323K |
|
435
MGM Resorts International
MGM
$9.85B
| $1.93M | 0.04% |
70,543
+6,296
| +10% | +$173K |
|
436
Constellation Brands
STZ
$25.8B
| $1.9M | 0.04% |
11,726
-1,878
| -14% | -$304K |
|
|
AVXS
437
DELISTED
AveXis, Inc. Common Stock
AVXS
| $1.9M | 0.04% |
+25,000
| New | +$1.9M |
|
438
United Therapeutics
UTHR
$17.8B
| $1.9M | 0.04% |
14,000
| – | – |
|
439
Bio-Rad Laboratories Class A
BIO
$7.86B
| $1.89M | 0.04% |
9,500
| – | – |
|
440
NOV
NOV
$4.92B
| $1.89M | 0.04% |
47,234
+6,123
| +15% | +$246K |
|
441
McCormick & Company Non-Voting
MKC
$18.8B
| $1.88M | 0.04% |
38,470
+33,936
| +748% | +$1.65M |
|
442
Keurig Dr Pepper
KDP
$37.5B
| $1.87M | 0.04% |
19,135
+2,294
| +14% | +$225K |
|
|
PARA
443
DELISTED
Paramount Global Class B
PARA
| $1.86M | 0.04% |
26,840
+4,824
| +22% | +$335K |
|
444
Pinnacle West Capital
PNW
$10.5B
| $1.85M | 0.04% |
+22,233
| New | +$1.85M |
|
|
TTPH
445
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $1.85M | 0.04% |
10,050
-8,650
| -46% | -$1.59M |
|
446
Sempra
SRE
$51.8B
| $1.84M | 0.04% |
33,228
+6,846
| +26% | +$378K |
|
447
Welltower
WELL
$113B
| $1.83M | 0.04% |
25,791
+6,574
| +34% | +$466K |
|
448
Thomson Reuters
TRI
$78.2B
| $1.82M | 0.04% |
36,855
-69,856
| -65% | -$3.44M |
|
449
Brown-Forman Class B
BF.B
$13B
| $1.81M | 0.04% |
61,316
+1,978
| +3% | +$58.5K |
|
450
Consolidated Edison
ED
$34.9B
| $1.81M | 0.04% |
23,316
+4,650
| +25% | +$361K |
|